Aratana Therapeutics, Inc. (NASDAQ:PETX) - Research analysts at William Blair upped their Q3 2017 EPS estimates for shares of Aratana Therapeutics in a note issued to investors on Monday. William Blair analyst J. Kreger now forecasts that the biopharmaceutical company will post earnings of ($0.25) per share for the quarter, up from their previous forecast of ($0.26). William Blair also issued estimates for Aratana Therapeutics’ Q4 2017 earnings at ($0.21) EPS, FY2017 earnings at ($1.05) EPS and FY2019 earnings at $0.30 EPS.
Several other brokerages have also commented on PETX. BidaskClub lowered shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday. Jefferies Group LLC set a $8.00 target price on shares of Aratana Therapeutics and gave the company a “buy” rating in a research note on Friday, August 4th. ValuEngine downgraded shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Zacks Investment Research downgraded shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. Finally, Stifel Nicolaus reduced their price target on shares of Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, May 10th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $10.00.
Shares of Aratana Therapeutics (PETX) opened at 6.07 on Wednesday. The stock’s market capitalization is $230.40 million. The stock’s 50 day moving average is $7.07 and its 200 day moving average is $6.46. Aratana Therapeutics has a 52 week low of $4.97 and a 52 week high of $10.73.
Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.29) by $0.03. Aratana Therapeutics had a negative net margin of 642.93% and a negative return on equity of 51.21%. The company had revenue of $5.16 million during the quarter, compared to analysts’ expectations of $4.50 million. During the same period in the previous year, the company earned $0.61 EPS. The business’s quarterly revenue was down 86.4% compared to the same quarter last year.
Large investors have recently bought and sold shares of the stock. Financial Counselors Inc. bought a new stake in Aratana Therapeutics during the first quarter valued at $101,000. American International Group Inc. boosted its stake in Aratana Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,354 shares during the last quarter. Janney Montgomery Scott LLC boosted its stake in Aratana Therapeutics by 7.9% in the second quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 1,200 shares during the last quarter. Ray Gerald L & Associates Ltd. boosted its stake in Aratana Therapeutics by 38.2% in the first quarter. Ray Gerald L & Associates Ltd. now owns 23,900 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 6,600 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY boosted its stake in Aratana Therapeutics by 17.9% in the first quarter. Metropolitan Life Insurance Co. NY now owns 25,619 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 3,883 shares during the last quarter. Hedge funds and other institutional investors own 67.85% of the company’s stock.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
